Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Current Deferred Revenue (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Current Deferred Revenue data on record, last reported at $35.0 million in Q4 2025.

  • For Q4 2025, Current Deferred Revenue changed N/A year-over-year to $35.0 million; the TTM value through Dec 2025 reached $35.0 million, changed N/A, while the annual FY2025 figure was $35.0 million, N/A changed from the prior year.
  • Current Deferred Revenue reached $35.0 million in Q4 2025 per RCUS's latest filing, down from $52.0 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $131.0 million in Q2 2025 and bottomed at $35.0 million in Q2 2023.
  • Average Current Deferred Revenue over 5 years is $81.9 million, with a median of $90.1 million recorded in 2022.
  • Peak YoY movement for Current Deferred Revenue: surged 965.3% in 2021, then plummeted 63.92% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $102.0 million in 2021, then dropped by 4.9% to $97.0 million in 2022, then tumbled by 63.92% to $35.0 million in 2023, then surged by 254.29% to $124.0 million in 2024, then tumbled by 71.77% to $35.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $35.0 million in Q4 2025, $52.0 million in Q3 2025, and $131.0 million in Q2 2025.